Changing
the Course of
Cardiovascular Disease
We translate our
world-class expertise
in cardiovascular signaling pathways into groundbreaking therapeutics for patients.
Discover new targets and novel drug candidates
Innovate using adaptive trial designs and precision medicine approaches
Acquire assets where we have unique insights into their use in CV disease
A Next Generation
Cardiovascular Company
We are addressing the continuing unmet needs of patients with cardiovascular disease through:
Groundbreaking clinical programs in PDE9 and CaMKII inhibition
Experienced team of CV experts and industry veterans with track records of success
Strategic portfolio approach driven by an in-house drug discovery group and a highly experienced search and evaluation team
Foundational partnerships with key strategics and investors, including an investment by Bain Capital to support current programs and pipeline expansion
We are advancing Two Groundbreaking Clinical Programs
Heart Failure: PDE9
PDE9 inhibition presents an opportunity to develop a foundational new treatment for patients with both types of chronic heart failure, HFrEF and HFpEF, with the potential for improved efficacy when added to guideline-directed medical therapy.
Rare arrhythmias and more common CV Diseases: CaMKII
CaMKII plays a critical role in regulating normal calcium signaling and cardiac function. CaMKII has a causal role in a number of cardiac diseases when it becomes hyperactivated.
Cardurion is the first company to successfully develop a CaMKII inhibitor and evaluate it in clinical studies. We are now well positioned to explore multiple cardiovascular diseases, including the rare and fatal genetic disease catecholaminergic polymorphic ventricular tachycardia (CPVT), as well as larger indications including heart failure and atrial fibrillation.
Contact Us
To request additional information or contact us, please fill out the contact form.
Massachusetts
78 Blanchard Road
Suite 200
Burlington, MA 01803, USA
Info@cardurion.com
617-863-8088
Japan
Cardurion Pharmaceuticals KK
26-1, Muraoka-Higashi 2-chome,
Fujisawa, Kanagawa 251-8555, Japan
Media Contact
Email: info@cardurion.com
